-+ 0.00%
-+ 0.00%
-+ 0.00%

NovaBridge Subsidiary Visara Doses First Patient in Phase 2b Trial of VIS-101 for Wet AMD

PUBT·11/18/2026 12:04:22
NovaBridge Subsidiary Visara Doses First Patient in Phase 2b Trial of VIS-101 for Wet AMD
  • NovaBridge Biosciences' majority-owned subsidiary Visara dosed the first patient in its ASCEND Phase 2b trial of VIS-101 for wet AMD.
  • The approximately 244-patient trial is being conducted in China with Everest Medicines.
  • ASCEND compares VIS-101 doses of 6 mg and 9 mg against 2 mg aflibercept administered every eight weeks.
  • Following monthly loading doses, VIS-101 treatment intervals could reach seven months; results will guide dose selection for global Phase 3 trials.
  • In Phase 2a, approximately 50% of treatment-naive patients receiving 6 mg remained retreatment-free six months after the last loading dose.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611180700PRIMZONEFULLFEED9880055) on November 18, 2026, and is solely responsible for the information contained therein.